Free Trial

Amneal Pharmaceuticals (AMRX) Competitors

Amneal Pharmaceuticals logo
$7.29 +0.13 (+1.82%)
Closing price 04:00 PM Eastern
Extended Trading
$7.35 +0.06 (+0.82%)
As of 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMRX vs. ROIV, RVMD, BPMC, BBIO, ELAN, VRNA, TLX, GRFS, TGTX, and LEGN

Should you be buying Amneal Pharmaceuticals stock or one of its competitors? The main competitors of Amneal Pharmaceuticals include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Verona Pharma (VRNA), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Grifols (GRFS), TG Therapeutics (TGTX), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.

Amneal Pharmaceuticals vs.

Amneal Pharmaceuticals (NASDAQ:AMRX) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, community ranking, dividends, profitability, analyst recommendations, institutional ownership and valuation.

In the previous week, Roivant Sciences had 2 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 10 mentions for Roivant Sciences and 8 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.55 beat Roivant Sciences' score of 1.26 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amneal Pharmaceuticals
8 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Roivant Sciences
7 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Amneal Pharmaceuticals presently has a consensus price target of $11.50, suggesting a potential upside of 56.57%. Roivant Sciences has a consensus price target of $17.50, suggesting a potential upside of 61.51%. Given Roivant Sciences' higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Amneal Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amneal Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Roivant Sciences
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00

Amneal Pharmaceuticals has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.

Amneal Pharmaceuticals has a net margin of -6.88% compared to Roivant Sciences' net margin of -119.54%. Roivant Sciences' return on equity of -14.05% beat Amneal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Amneal Pharmaceuticals-6.88% -346.26% 4.85%
Roivant Sciences -119.54%-14.05%-12.81%

Roivant Sciences has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amneal Pharmaceuticals$2.83B0.81-$83.99M-$0.04-183.63
Roivant Sciences$122.59M63.07$4.35B-$0.15-72.23

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 26.6% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Roivant Sciences received 35 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 95.24% of users gave Amneal Pharmaceuticals an outperform vote while only 78.57% of users gave Roivant Sciences an outperform vote.

CompanyUnderperformOutperform
Amneal PharmaceuticalsOutperform Votes
20
95.24%
Underperform Votes
1
4.76%
Roivant SciencesOutperform Votes
55
78.57%
Underperform Votes
15
21.43%

Summary

Amneal Pharmaceuticals and Roivant Sciences tied by winning 9 of the 18 factors compared between the two stocks.

Get Amneal Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMRX vs. The Competition

MetricAmneal PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.31B$6.54B$5.40B$8.48B
Dividend YieldN/A2.64%5.28%4.16%
P/E Ratio-10.828.8327.1619.90
Price / Sales0.81257.03393.19138.25
Price / Cash5.8065.8538.3234.64
Price / Book104.936.476.794.58
Net Income-$83.99M$143.70M$3.23B$248.14M
7 Day Performance-1.01%1.27%0.18%0.35%
1 Month Performance-1.80%2.40%8.10%9.66%
1 Year Performance13.88%1.09%19.22%8.99%

Amneal Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMRX
Amneal Pharmaceuticals
3.3601 of 5 stars
$7.29
+1.8%
$11.50
+57.8%
+11.0%$2.28B$2.83B-10.727,600Positive News
ROIV
Roivant Sciences
1.9014 of 5 stars
$10.87
-0.6%
$17.50
+61.0%
-1.0%$7.76B$122.59M-72.46860Positive News
Upcoming Earnings
RVMD
Revolution Medicines
4.3994 of 5 stars
$39.77
+2.5%
$67.08
+68.7%
+4.8%$7.41B$742,000.00-11.08250Positive News
BPMC
Blueprint Medicines
2.6008 of 5 stars
$101.50
+1.2%
$126.56
+24.7%
-1.3%$6.56B$562.12M-93.98640Positive News
Analyst Revision
BBIO
BridgeBio Pharma
4.5003 of 5 stars
$33.34
+1.1%
$57.09
+71.2%
+19.3%$6.33B$127.42M-11.70400Positive News
ELAN
Elanco Animal Health
3.1345 of 5 stars
$12.66
-0.1%
$15.17
+19.8%
-24.6%$6.29B$4.43B31.669,800Positive News
VRNA
Verona Pharma
1.8102 of 5 stars
$75.06
+3.3%
$81.50
+8.6%
+523.4%$6.09B$118.54M-39.0930Positive News
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/A$16.60
+2.5%
$22.00
+32.5%
N/A$5.61B$783.21M0.00N/APositive News
High Trading Volume
GRFS
Grifols
2.8828 of 5 stars
$8.11
-0.2%
N/A+12.6%$5.58B$7.21B6.9326,300
TGTX
TG Therapeutics
3.8114 of 5 stars
$34.57
+1.0%
$40.80
+18.0%
+106.9%$5.49B$386.39M-345.67290Positive News
LEGN
Legend Biotech
3.709 of 5 stars
$28.91
-0.5%
$76.20
+163.6%
-30.2%$5.31B$728.30M-30.431,070

Related Companies and Tools


This page (NASDAQ:AMRX) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners